Podcasts about UC

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Wednesday, June 25th, 2025Today, former DoJ lawyer Erez Reuveni issues a bombshell whistleblower account of Emil Bove's intentional defiance of court orders on the eve of his judicial confirmation hearing; US intelligence assessments indicate that Iran's nuclear sites were not destroyed and they can be back up and running in a few months; Florida is paving over the Everglades to build its own concentration camp; a federal judge has blocked Trump's termination of University of California research grants; the Senate parliamentarian nixes the public lands selloff in the Billionaire Bailout Bill; four tech execs are sworn in as lieutenant colonels in the Army; Senator Lisa Murkowski signals she may turn Independent and caucus with Democrats; House Dems choose youth over seniority in the House Oversight ranking member election; and Allison delivers your Good News.Thank You, DeleteMeGet 20% off your DeleteMe plan when you go to joindeleteme.com/DAILYBEANS and use promo code DAILYBEANS at checkout. Thank You, Daily LookFor 50% off your order, head to DailyLook.com and use code DAILYBEANS. Thank You, CBDistilleryUse promo code DAILYBEANS at CBDistillery.com for 25% off your purchase.  Specific product availability depends on individual state regulations.Check out Dana's social media campaign highlighting LGBTQ+ heroes every day during Pride Month -  Dana Goldberg (@dgcomedy.bsky.social)Guest: Martha BarnetteFriends with Words Adventures in Languageland - book by Martha BarnetteMarthaBarnette.comA Way with Words Podcast@marthabarnette - BlueSky, Martha Barnette (@martha.barnette) - Instagram, MarthaBarnette - twitterStoriesStrike Set Back Iran's Nuclear Program by Only a Few Months, U.S. Report Says | The New York TimesLive updates: Trump lashes out at Israel and Iran amid accusations of ceasefire violations | NBC NewsWhat Big Tech's Band of Execs Will Do in the Army | WIREDFlorida Builds ‘Alligator Alcatraz' Detention Center for Migrants in Everglades | The New York TimesHouse Democrats Elect Robert Garcia for Top Oversight Post | The New York TimesJudge blocks Trump's termination of UC research grants | Courthouse News ServiceMurkowski suggests she could become an Independent in the right circumstance - Live Updates | POLITICOGOP budget bill could threaten public lands, conservation groups voice opposition | NBC MontanaFrom The Good Newsuncomplicatedkitchen.org'No Kings' Protests see thousands in San Antonio area speak out, joining national movementGay Men's Chorus Of Washington, DCPotomac Fever (@potomac.fever) -  Instagram‘Get ready to sweat!' The animal mega-marathon stampeding from the Congo to the Arctic | Stage | The GuardianBe Biscuit's Hero - AZ Humane SocietyStar 67 - The Daily Beans - Apple PodcastsReminder - you can see the pod pics if you become a Patron. The good news pics are at the bottom of the show notes of each Patreon episode! That's just one of the perks of subscribing! patreon.com/muellershewrote Federal workers - feel free to email me at fedoath@pm.me and let me know what you're going to do, or just vent. I'm always here to listen.Share your Good News or Good TroubleMSW Good News and Good Trouble Check out other MSW Media podcastshttps://mswmedia.com/shows/Subscribe for free to MuellerSheWrote on Substackhttps://muellershewrote.substack.comFollow AG and Dana on Social MediaDr. Allison Gill Substack|Muellershewrote, BlueSky|@muellershewrote , Threads|@muellershewrote, TikTok|@muellershewrote, IG|muellershewrote, Twitter|@MuellerSheWrote,Dana GoldbergTwitter|@DGComedy, IG|dgcomedy, facebook|dgcomedy, IG|dgcomedy, danagoldberg.com, BlueSky|@dgcomedyHave some good news; a confession; or a correction to share?Good News & Confessions - The Daily Beanshttps://www.dailybeanspod.com/confessional/ Listener Survey:http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=shortFollow the Podcast on Apple:The Daily Beans on Apple PodcastsWant to support the show and get it ad-free and early?Supercasthttps://dailybeans.supercast.com/Patreon https://patreon.com/thedailybeansOr subscribe on Apple Podcasts with our affiliate linkThe Daily Beans on Apple Podcasts

At the time of this recording, we are preparing to head into 4th of July in just over one week which is a holiday all about freedom How do YOU define freedom? Let's talk about that today and how you can find/create more freedom in your life! FIND OUT MORE ABOUT MAGDALENA GRACE HERE or TO SIGN UP FOR HER UPCOMING ABUNDANCE ALCHEMIST IN PERSON WORKSHOPS OR HEALTHY N WEALTHY N WISE RETREATS BOOK A RUNES READING AND SIGN UP FOR HER WORKSHOPS & MORE! www.MagdalenaGrace.com   JOIN OUR HEALTHY N WEALTHY N WISE ONLINE ACADEMY  www.microdosingforhealth.com    BUY ME A COFFEE OR DONATE FOR SCHOLARSHIP FUND FOR HEALING CLIENTS IN NEED https://venmo.com/u/lotusthrone   MORE ALCHEMY OPPORTUNITIES FOR YOUR BEST HEALTH, WEALTH AND RELATIONSHIPS www.SanDiegoKambo.com  www.KundaliniFallbrook.com  www.LotusThroneSanctuary.com   WANNA SIGN UP AND BE A PLEDGING PATRON FOR HEALTHY N WEALTHY N WISE - SAVING LIVES AND CREATING MORE ABUNDANCE FOR OTHERS?  https://patron.podbean.com/magdalena     SUBSCRIBE TO HER YOUTUBE CHANNEL: https://www.youtube.com/@UC_l0t_6TBbZ1q9Q0wKZz89Q   

Workers Against Ice Petition: Oakland Children's Hospital Strike Fund: After a brief detour discussing the necessity for labor to unite against the US-Israeli war on Iran, we dive into our regular labor headlines. This week we've got followups with striking grocery workers, beverage distribution workers, tabletop game store employees, teachers, and farmworkers. Our first story returns to one of the more horrific forms of labor in this country, prison slavery, as incarcerated workers in Alabama fight to just have the state follow its own laws. Next, gig workers in India are facing dystopian new conditions of ten minute worker deliveries. Research assistants at the University of Illinois Urbana-Champaign are on the verge of forming one of the largest single campus grad unions in the country. Finally, healthcare workers at Oakland Children's Hospital are on strike after their employers in the UC system are proposing to slash their benefits. Join the discord: discord.gg/tDvmNzX  Follow the pod at instagram.com/workstoppage, @WorkStoppagePod on Twitter,  John @facebookvillain, and Lina @solidaritybee

Another HUGE week (I feel like I say that every week!) in the energies A new moon is upon us and it's time to set intentions in health, wealth and relationships with Magical Mags Runes reading and ritual The New Moon in Cancer in 2025 will occur on June 25th at 3:31 am PT. This New Moon is happening during Cancer season, which is a time for focusing on home, family, and emotional renewal. It's a time to connect with your emotions, nurture yourself, and explore new definitions of home Jupiter is also conjunct the sun for EXPANSION AND POTENCY on steroids Tune in to the divination reading and see what  comes thru for YOU What intentions will you set? Bring a journal 1:30 inhalation and grounding 2:55 current astrology 8:29 announcements of transformational webinar and workshop 9:58 runes pull/reading 19:25 animal medicine card pull 23:00 runes singing/intonation 26:35  write out your new moon in cancer sacred intention for health/wealth or relationships 29:00 donations for my suicide and mental health awareness scholarships   Hire her for your own personal 1-1 reading at www.MagdalenaGrace.com   FIND OUT MORE ABOUT MAGDALENA GRACE HERE or TO SIGN UP FOR HER UPCOMING ABUNDANCE ALCHEMIST IN PERSON WORKSHOPS OR HEALTHY N WEALTHY N WISE RETREATS BOOK A RUNES READING AND SIGN UP FOR HER WORKSHOPS & MORE! www.MagdalenaGrace.com   JOIN OUR HEALTHY N WEALTHY N WISE ONLINE ACADEMY  www.microdosingforhealth.com    BUY ME A COFFEE OR DONATE FOR SCHOLARSHIP FUND FOR HEALING CLIENTS IN NEED https://venmo.com/u/lotusthrone   MORE ALCHEMY OPPORTUNITIES FOR YOUR BEST HEALTH, WEALTH AND RELATIONSHIPS www.SanDiegoKambo.com  www.KundaliniFallbrook.com  www.LotusThroneSanctuary.com   WANNA SIGN UP AND BE A PLEDGING PATRON FOR HEALTHY N WEALTHY N WISE - SAVING LIVES AND CREATING MORE ABUNDANCE FOR OTHERS?  https://patron.podbean.com/magdalena     SUBSCRIBE TO HER YOUTUBE CHANNEL: https://www.youtube.com/@UC_l0t_6TBbZ1q9Q0wKZz89Q 

The legend in the small, coastal town of Antonio Bay is of a ship lured to the land and swallowed up by a mysterious thick cloud as it sank. The locals say when the fog returns, the dead will arise from their watery graves.The Fog, directed by John Carpenter, fits quite nicely into Retro Reel 2025. It stars horror greats such as Adrienne Barbeau, Jamie Lee Curtis, Tom Atkins, and Hal Holbrook and like most Carpenter films, features an electric soundtrack. The film gives off eerie vibes and has multiple character stories that are bridged together quite nicely as the secrets of Antonio Bay are revealed throughout the movie. While the film is not without its flaws, it's fun to watch a mystery, ghost story, and revenge plot all wrapped into one. Watch the movie and catch our review.Subscribe to our YouTube channel @thefinalpodcast  Join the Discord | https://discord.gg/UFtVP243Follow us on Facebook The Final Podcast Follow us on Instagram @thefinalpodcastFollow us on X @thefinalpodeverMusic Credit: Karl Casey @ White Bat Audiohttps://www.youtube.com/channel/UC_6h...What should we review next? Toss us a vibe and send over a recommendation!

UC's Basketball GM and newly-minted NBA Champion Corey Evans joins Mo.

UC's Basketball GM and newly-minted NBA Champion Corey Evans joins Mo.

In this episode of UC Today, host Rob Scott sits down with Garth Landers, Director of Global Product Marketing at Theta Lake, to tackle one of the most urgent and overlooked risks in Unified Communications today: voice compliance.As enterprises migrate from legacy PBX systems to cloud-first platforms like Microsoft Teams Phone and Zoom Phone, many are leaving a dangerous gap in their compliance stack. Voice is no longer isolated — it's deeply integrated with chat, video, AI tools, and screen sharing — yet many compliance strategies are still built for a siloed world.Why watch this? Because as AI transforms UC platforms and vendors roll out new features at lightning speed, knowing how to govern all forms of communication data — including voice — is critical to avoid regulatory risks and future-proof your organization.Key discussion points include:Why voice compliance continues to lag behind messaging and video — and why that's a risk.The top challenges enterprises face when migrating voice to cloud platforms like Teams & Zoom.How to ensure consistent compliance across hybrid UC environments with multiple voice channels.How Theta Lake's solutions enable real-time risk detection and flexible archiving for voice, chat, video, and AI-generated content.Practical advice for IT and compliance leaders preparing for AI-driven voice features and virtual agents.Next Steps: If your organization is modernizing its UC stack or exploring AI-powered communication features, now is the time to review your compliance readiness. Explore how Theta Lake can help you bridge the gap and stay ahead of regulatory demands.

Expert Panel: Amy Hobek, PhD, CCC-SLP, Fé González Murray, EdD, CCC-SLP, Vishnu KK Nair, Archie Soelaeman, Betty Yu and Reem KhamisTake ACTION HERE: Changes to 2020 certification standards feedback. Survey. (n.d.). https://www.surveymonkey.com/r/2020_Cert_ChangesThis episode will be available for 0.1 ASHA CEU on July 2Correction Note from Dr. Betty: “During the recording I referred to the executive order targeting associations with assets of $500 million or more. I thought ASHA met that criteria but actually ASHA's net assets are around $174 million.”In this episode, Michelle and Erin host an all start line up of colleagues from across the globe to discuss ASHA's Proposed Changes to the “2020 Certification Standards” and the long-term ramifications that these changes could have for our profession. This conversation is timely in that there are only a matter of days, roughly 3 weeks or less, for audiologists and speech-language pathologists (including students) to write in and advocate to ASHA on whether the proposed changes to the 2020 Certification Standards should be accepted… changes that remove key words and language that were hard fought to obtain. Be informed that this conversation does address political rationale behind the changes and offer a plethora of resources for individuals to grow their knowledge regarding the long-term ramifications of these proposed changes… but it ends with resources on how to make your voice heard! So, come join the ladies of “First Bite” and ADVOCATE!About the Panel: Amy Hobek, PhD, CCC-SLP is an Associate Professor of Communication Sciences and Disorders at the University of Cincinnati. Her teaching and scholarship focus on equity and inclusion, with an emphasis on valuing and legitimizing cultural and linguistic variations in these areas within individuals, families, and communities. She is also a licensed speech language pathologist providing clinic supervision of graduate students in a culturally and linguistically diverse preschool setting on UC's campus. She is a co-chair of the Cultural Humility Task Force of the National Black Association of Speech Language and Hearing. She is a topic co-chair of Equity, Inclusion, and Cultural-Linguistic Diversity for the ASHA 2025 Convention. Professor Reem Khamis (also known as Reem Khamis-Dakwar) is Professor Emerita at Adelphi University and Chair of the Department of Communication Sciences and Disorders at Long Island University (LIU) Brooklyn. Her expertise centers on language development, processing, and clinical services within the sociolinguistic context of diglossia and diverse populations. Dr. Khamis is co-founder of the Journal of the Critical Study of Communication and Disability (JCSCD) and a co-founding member of the Speech, Language, and Hearing Scientists Equity Action Collective. She currently serves as Language Section Editor for the Journal of Speech, Language, and Hearing Research (JSLHR). She received the Excellence in Diversity Award in 2020 from the Council of Academic Programs in Communication Sciences and Disorders (CAPCSD). Fé González Murray, EdD, CCC-SLP is an Associate Clinical Professor in the Department of Communication Sciences and Disorders at Northern Arizona University. Prior to joining the NAU faculty, she worked for 25 years as an English/Spanish bilingual speech-language pathologist in various settings, most notably in public schools serving Indigenous American, migrant, and immigrant populations. In addition to teaching and supervising clinical rotations, she facilitates workshops nationally and internationally on topics related to responsive practice with culturally and linguistically diverse individuals and their families, including multilingualism and collaboration with interpreters. Vishnu KK Nair is a lecturer in the School of...

Send us a textWhen you're battling inflammatory bowel disease, the wounds aren't always visible. Beyond the physical symptoms lies a reality many patients face but few discuss openly – the psychological impact of medical trauma.Dr. Christina Jagielski, clinical health psychologist at Michigan Medicine, brings her expertise to this powerful conversation about trauma-informed care in the IBD community. With surprising candor, she reveals how she discovered that approximately half of gastroenterologists avoid screening for trauma history – not because they don't care, but because they feel unprepared to respond appropriately to what patients might share.Through Robin's emotional personal story of emergency room panic attacks and medical gaslighting, we witness firsthand how past medical experiences shape current healthcare interactions. The conversation dives deep into practical strategies for both patients and providers: how to communicate triggers without reliving trauma, why certain medical settings feel unsafe, and what small changes can make enormous differences in patient comfort.Dr. Jagielski challenges the longstanding approach of selective trauma screening based on gender or diagnosis, advocating instead for universal trauma-informed care. "People living with IBD are so much more than their labs and test results," she reminds us, emphasizing that acknowledging patients' lived experiences is just as crucial as treating their physical symptoms.Whether you're a patient who's experienced medical trauma, a healthcare provider seeking to create safer spaces, or someone supporting a loved one with IBD, this episode offers transformative insights into healing the hidden psychological wounds of chronic illness. Listen now to start breaking down the barriers between physical and psychological care in the IBD journey.Links: Dr. Christina Jagielski"Had a Traumatic Medical Experience? Don't Ignore it"- article in Psychology Today by Dr. Tiffany TaftJournal Article on Medical Gaslighting- Dr. Jagielski, Dr. Taft, and Dr. FussLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

While one part of the German government tries to decide whether it's against international law to be sending weapons to a country that has started a war while committing genocide, another department is trying to figure out why one in four immigrants wants to leave the country. Meanwhile, we've apparently decided that enough Nazis are dead now so it's ok to have a military veterans' day. Plus, a tiny morsel of good news about urban speed limits. Cheers!Megan's Megacan theme song by Eden Ottignon from ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Planet OTT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Buy us a round, ask us a question! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/megansmegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Or follow us on whichever psychotic billionaire's data-fracking machine you like best:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/megansmegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/MegansMegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UC-o_U5nqe4_-yKfOm1CXOPA⁠⁠⁠⁠⁠

A child's comic book brings five tales of terror to life.Retro Reel 2025 rolls on with an anthology movie we enjoy watching every time. Creepshow, directed by George A. Romero, features an all-star cast of Hal Holbrook, Leslie Nielsen, Ted Danson, and Adrienne Barbeau among many others in five horror tales that seem to get better and better as the movie continues. The blend of comedy and horror are done so well and the overarching story of the tales coming from a child's comic book is an excellent touch. The stories are clever, fun, and stand out in a genre that features so many anthology films. Watch the movie and catch our review.Subscribe to our YouTube channel @thefinalpodcast  Join the Discord | https://discord.gg/UFtVP243Follow us on Facebook The Final Podcast Follow us on Instagram @thefinalpodcastFollow us on X @thefinalpodeverMusic Credit: Karl Casey @ White Bat Audiohttps://www.youtube.com/channel/UC_6h...What should we review next? Toss us a vibe and send over a recommendation!

Safety in Japan, Kyoto Trip, Fairness, and more! 日本の治安、京都旅行、平等とはなど！ Join our Discord: https://discord.gg/VGSd94Tp4P Join our Book Club! https://ko-fi.com/i/IF1F01EWI60 Support on ko-fi:  https://ko-fi.com/lazyfluency Main channel:  https://www.youtube.com/channel/UC-8_djC5_aV4Mi3o3fuLPLA Send us questions at:  lazyfluency@gmail.com  

Join Magdalena for a potent Runes reading If ever there was a time to embrace these readings for health, wealth and relationship wisdom...it is this week! It's going to be a breakthru week for many IF you choose to work with these energies and allow the power of the Runes to awaken/stir something inside of you Join in for some POTENT journal prompts along the way toward the end as well FIND OUT MORE ABOUT MAGDALENA GRACE HERE or TO SIGN UP FOR HER UPCOMING ABUNDANCE ALCHEMIST IN PERSON WORKSHOPS OR HEALTHY N WEALTHY N WISE RETREATS BOOK A RUNES READING AND SIGN UP FOR HER WORKSHOPS & MORE! www.MagdalenaGrace.com   JOIN OUR HEALTHY N WEALTHY N WISE ONLINE ACADEMY  www.microdosingforhealth.com    BUY ME A COFFEE OR DONATE FOR SCHOLARSHIP FUND FOR HEALING CLIENTS IN NEED https://venmo.com/u/lotusthrone   MORE ALCHEMY OPPORTUNITIES FOR YOUR BEST HEALTH, WEALTH AND RELATIONSHIPS   www.KundaliniFallbrook.com  www.LotusThroneSanctuary.com   WANNA SIGN UP AND BE A PLEDGING PATRON FOR HEALTHY N WEALTHY N WISE - SAVING LIVES AND CREATING MORE ABUNDANCE FOR OTHERS?  https://patron.podbean.com/magdalena     SUBSCRIBE TO HER YOUTUBE CHANNEL: https://www.youtube.com/@UC_l0t_6TBbZ1q9Q0wKZz89Q   

The University of Cincinnati Bearcats have a hell of a new home for their football program. The indoor practice facility costed 134 million and now fully cements UC's facilities as Big 12 caliber. Plus, Dayton will come to Fifth Third this season as a part of a home and home. Chuck Walter, Nick Niehaus and Eric Lilly break it all down.

Tony talks with Bob Mangine from UC and NovaCare on ESPN 1530!

Tony talks with Bob Mangine from UC and NovaCare on ESPN 1530!

UC's Director of Athletics John Cunningham joined us to discuss the school's new indoor complex and the revenue sharing era of college sports, on ESPN1530.Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

UC's Director of Athletics John Cunningham joined us to discuss the school's new indoor complex and the revenue sharing era of college sports, on ESPN1530.Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

"Customers don't want three different dashboards — they want one pane of glass." — Adam Derkey, Product Architect, Unimax At Cisco Live 2025 in San Diego, Technology Reseller News publisher Doug Green sat down with Adam Derkey of Unimax to explore Sentinel, the company's cloud-native, multi-vendor CDR (Call Detail Record) and analytics tool. Sentinel, now live for nearly a year, provides a single interface for monitoring call data across Cisco, Microsoft Teams, Avaya, and other platforms — eliminating the need for disparate reporting tools. Designed from the ground up as a cloud-first solution in Microsoft Azure, Sentinel simplifies the overwhelming volume of CDR data generated by modern UC systems, offering standardized dashboards, visualizations, and actionable insights. “You don't have to understand how a Teams call record works versus a Cisco record. We normalize all of it so you can focus on what matters,” said Derkey, who led the product's design. Unlike Unimax's flagship Second Nature, which streamlines MACD (Moves, Adds, Changes, and Deletes) management, Sentinel provides deep analytics on system performance and usage. Together, the two solutions create a powerful lifecycle platform: one for UC system control, the other for operational intelligence. Key Features of Sentinel: Multi-vendor CDR normalization (Cisco, Avaya, Teams, etc.) Unified dashboards and visual analytics Rapid cloud deployment (in as little as a week) Open availability to both existing and new Unimax customers Unimax is already seeing strong demand — from both long-time customers and net-new prospects — especially among enterprises seeking simplified UC reporting and resellers who want to offer bundled visibility solutions. Sentinel is also helping channel partners open new conversations with Cisco users and decision-makers. “It's a door-opener,” said Derkey, “especially for those who want to consolidate UC analytics without adding another vendor.” To learn more, visit unimax.com.

"We're here to take the complexity out of unified communications — and turn it into simplicity." — Todd Remely, Unimax At Cisco Live 2025 in San Diego, Technology Reseller News publisher Doug Green caught up with Todd Remely of Unimax to explore how the company is streamlining unified communications (UC) management for enterprises and partners alike. With over 30 years in business, Unimax is a veteran in the telecom software space. Their tools help organizations manage Cisco, Microsoft Teams, Zoom, and Avaya UC systems more efficiently — and that value was on full display across two booths at Cisco Live: one in the Collaboration Village (highlighting Webex integration) and another on the main show floor. Three Ways Unimax Delivers Simplicity in Complex UC Environments: Second Nature A power-user interface that layers over Cisco and other major UC platforms, enabling administrators to perform complex MACDs (moves, adds, changes, deletes) and configuration tasks like provisioning, routing, and device pool management — all from one streamlined dashboard. Automation Platform Unimax enables full automation of provisioning and deprovisioning processes. Their platform integrates with Active Directory, ServiceNow, Remedy, HRIS systems, and any REST API-enabled tool, drastically reducing time and human error in user onboarding and offboarding. HelpOne A lightweight interface that empowers Tier 1 help desk agents to complete routine MACDs — such as password resets — without telecom expertise, freeing up UC teams to focus on higher-priority work. Remely noted strong engagement from MSPs and resellers, many of whom use Unimax's multi-tenant solutions to manage customer UC systems at scale. "We're solution-focused," he said. "And we love working with end users — because that's where the real problems are, and that's where we can help most." For more information or to request a demo, visit unimax.com or contact the team at tellmemore@unimax.com.

Tony talks with UC AD John Cunningham about the opening of the new Indoor Practice Facility at UC and the house settlement, on ESPN 1530!

In this episode of The Collaboration Space podcast. Nancy is joined by John Bailey from AVI-SPL and Crestron's Brad Hintze. The group discusses how AI is advancing rapidly and how AVI-SPL and Crestron can help you accelerate your path to AI readiness. They also share insights on how the latest AV technology enables AI and ways to keep up with the rapid changes in AI capabilities.Learn more about AVI-SPL and Crestron.Watch the video podcast on YouTube.Get AV and unified communications news delivered to your inbox.Follow AVI-SPL: Linkedin X YouTube

Join Kristian McCann for an insightful conversation with Ryan Zoehner, CEO of Algo, as he reveals how his company is tackling one of UC's biggest challenges: integration with your AV technology.With over 55 years of innovation behind them, Algo has positioned itself as the critical bridge between legacy systems and modern UC infrastructure. Zoehner shares how his team's education-first approach is helping partners and customers navigate the complex landscape of IP endpoint deployment, empowering frontline companies to gain control of their enterprise communications strategy.Discover how Algo is transforming the UC landscape by focusing on what others overlook—the final mile of UC migration. Key insights from this conversation:Why Algo targets end-user organizations directly rather than competing solely on channel partnershipsHow Algo's products seamlessly connect with existing UC platforms without disrupting current workflowsThe company's unique approach to building partner expertise through comprehensive training and support AIHow AI is reshaping communication endpoints and creating new opportunities for frontline connectivityWhy the "final mile" represents the biggest untapped opportunity in unified communicationsAlgo's 55+ year heritage positions them uniquely to solve these challenges

SUBSCRIBE to The One to Go Show presented by ImpactHealth SharingSoil & Ag Solutions- https://www.agconcepts.com/  320-219-3542Fast Lane Motorsports and powdercoating- http://www.fastlanemotorsports.orgEastCentral Sports- http://www.eastcentralsports.comFB- https://www.facebook.com/OnetoGoShowSpotify: https://open.spotify.com/episode/4fO19zPyhuwqb74Ut3jgho?si=clWSn-DVQkmp8W_f95p4IgTikTok- @theonetogoshowSnapchat-@theonetogoshowRumble:  https://rumble.com/v57phvx-71524-the-one-to-go-show-presented-by-impact-health-sharing.htmlYouTube: https://www.youtube.com/channel/UC_r_TSMx2XEfMfJ9Vc1ez0w?view_as=subscriberWe'd like to hear from you: theonetogoshow@gmail.comA productionof G.O.A.T. Sports Media LLC

The Bengals and Shemar Stewart need an adult to handle their dispute and Mo has just the guy. The Reds lose their final game in Cleveland, but Mo talk's about the performance Andrew Abbott put on last night. UC's Athletic Director John Cunningham talks latest news with the Bearcats, Kelsey Conway live from Bengals minicamp and more!

In this episode, Tina sits down with Nir Salomon, co-founder of Evinature and director of the Integrative Gastroenterology Unit at Sheba Medical Center. Nir shares the origin story behind curQD, a scientifically backed supplement designed to support those living with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. They dive into the personalized, integrative approach his team uses, the clinical research supporting curQD, and how it's helping patients worldwide. Nir also introduces Exhale, a new product aimed at reducing stress and supporting gut-brain health. Here's what you'll learn: - What is the CurQD Protocol and how does it work? - The science behind Evinature's Gut Health Assessment - Is it safe to take long-term? - Does it work differently for Ulcerative Colitis vs. Crohn's Disease? - The type of results patients are seeing - How stress and the nervous system affect symptoms - Why Nir believes UC remission doesn't need to be a lifetime struggle Take Evinature's Gut Health Assessment: https://shop.evinature.com/953 Connect with Tina Haupert: https://carrotsncake.com/ Facebook: Carrots 'N' Cake https://www.facebook.com/carrotsncake Instagram: @carrotsncake https://www.instagram.com/carrotsncake YouTube: Tina Haupert https://www.youtube.com/user/carrotsncake Pinterest: Carrots 'N' Cake Hormone Testing & Nutrition Coaching https://www.pinterest.com/carrotsncake/ About Tina Haupert: Tina Haupert is the owner of Carrots ‘N' Cake as well as a Certified Nutrition Coach and Functional Diagnostic Nutrition Practitioner (FDN-P). Tina and her team use functional testing and a personalized approach to nutrition to help women find balance within their diets while achieving their body composition goals. Connect with Nir Salomon: https://evinature.com/ Facebook: https://www.facebook.com/evinature Instagram: https://www.instagram.com/evinature/ Tiktok: https://www.tiktok.com/@evinature LinkedIn: https://www.linkedin.com/company/evinature/ About Nir Salomon: Founder & Director of the Integrative Gastroenterology unit at Sheba Medical Center. Co-founder and Head of R&D at Evinature. After founding the Integrative Gastroenterology unit at Sheba Medical Center, Nir Salomon launched a decade-long research project with Professor Shomron Ben-Horin to advance the full potential of neutraceutical therapies for Inflammatory Bowel Disease. From 2011 to 2022, Salomon led a series of successful trials on the combined use of gut-directed curcumin and Qing Dai (CurQD®) on patients with UC, earning prestigious awards for “breakthrough innovation” and “clinical merit” in his work. His multi-center, international, investigator-initiated RCT on CurQD® was presented at the Crohn's and Colitis Foundation of America (CCFA), where it was awarded Poster of Distinction. In 2021, Salomon and Ben-Horin founded Evinature in partnership with Sheba Medical Center, (one of Newsweek's top 10 hospitals) to provide affordable, accessible, and effective therapies to IBD patients. Salomon lectures worldwide, advocating integrative, evidence-based therapies at prominent medical conferences. He is currently building a global network of leading IBD doctors to facilitate collaborative research projects in the field of nutraceuticals with an aim to advance medical accessibility for patients worldwide.

Hello tubby turds!  Join the guys this week for the most important podcast since the last podcast that they did.  Chris tells us why he hates California this week while Jason defends Pablo at Home Depot but both agree that if you're waiving a Mexican flag above burning cars then you should get you deported.   Should the Bengals have waived Germaine Pratt?  Why did Chris leave a "date" right after getting squirted on?  Jason watches a tweaker attack a couple of hippies at a park by UC.  Chris gets yelled at by a girl with special needs, meanwhile Jason is a hero for supporting them.  Elon and Trump don't like each other, Kash Patel stays in his lane instead of doing his job, andTrey Hendrickson isn't voluntarily working out for the Bengals.  The guys get to the bottom of all of this and end world hunger in the process.  There is nothing these losers can't figure out.  Join!

Dr. Pat J. Brown (UC Davis) discusses exciting new clonal rootstocks being developed by a team of UC and USDA researchers. Pat is looking for growers to trial these new clones, in particular K3 an exciting new rootstock that has produced good growth, yield, and very low crown gall. You can contact Pat at pjbrown@ucdavis.edu. Please also CC your local UCCE walnut farm advisor. Come to an upcoming extension meeting!In the Sacramento Valley: North Sac Valley Groundwater and SGMA is on Tuesday, June 24Save the date for Prune Research Tour Part 2 on Tuesday, July 15 In the San Joquin Valley: The Almond Board of California is hosting a Production Summit on Wednesday, June 18 where you can hear from researchers on advances in almond production research. The views, thoughts, and opinions expressed are the speaker's own and do not represent the views, thoughts, and opinions of the University of California. The material and information presented here is for general information purposes only. The "University of California" name and all forms and abbreviations are the property of its owner and its use does not imply endorsement of or opposition to any specific organization, product, or service.Follow us on Twitter! @SacOrchards and @SJVtandvThank you to the Almond, Pistachio, Prune, and Walnut Boards of California for their kind donations. Thank you to Muriel Gordon for the music.

Sheriff Dan Gillis investigates a series of murders and odd events in the small coastal town of Potter's Bluff.Retro Reel returns with a movie like no other. There's something about small town murder mysteries that are always interesting. Now just add horror and supernatural elements to that and you get Dead & Buried, a movie that doesn't get the appreciation it deserves. It fully captures that creepy small town feel as characters start dropping dead in the strangest circumstances and it seems like the sheriff is the only person trying to uncover the truth behind the murders. The movie features a lot of crazy death scenes and just when it seems like the mystery is solved, there are more twists coming, which makes this film so enjoyable. Watch the movie and catch our review.Subscribe to our YouTube channel @thefinalpodcast  Join the Discord | https://discord.gg/UFtVP243Follow us on Facebook The Final Podcast Follow us on Instagram @thefinalpodcastFollow us on X @thefinalpodeverMusic Credit: Karl Casey @ White Bat Audiohttps://www.youtube.com/channel/UC_6h...What should we review next? Toss us a vibe and send over a recommendation!

Japan's Lottery System, Extremism in Japan, Diminishing Returns of Pronunciation, and more! 日本の抽選システム、日本の過激化、発音の収穫逓減など！ Join our Discord: https://discord.gg/VGSd94Tp4P Join our Book Club! https://ko-fi.com/i/IF1F01EWI60 Support on ko-fi:  https://ko-fi.com/lazyfluency Main channel:  https://www.youtube.com/channel/UC-8_djC5_aV4Mi3o3fuLPLA Send us questions at:  lazyfluency@gmail.com  

Sobre la investigación “De lo convencional a lo extremo: perfilando las bases de apoyo de la derecha chilena”, Ramón Ulloa y Angélica Bulnes conversaron con Cristóbal Rovira, académico del Instituto de Ciencia Política UC, autor de la investigación.

Watch on YouTube.In the June 2025 edition of the Microsoft Teams News Show, host Rob Scott from UC Today is joined by Tom Arbuthnot of Empowering.Cloud and a seasoned panel of experts for a fast-paced breakdown of what's shaping the Microsoft Teams ecosystem. Fresh off his holiday and full of insights, Tom unpacks the biggest headlines from Microsoft Build, the newest Teams collaboration features, Copilot updates, Teams Phone innovations, and what to expect from key events like InfoComm, CCW Las Vegas, and Commsverse UK.With AI deepening its roots across the Microsoft 365 landscape, this episode takes you inside the latest announcements — including multi-agent orchestration, threaded messages, live transcription, speaker recognition in Android rooms, and more.Key Discussion Points:Copilot Breakthroughs at Microsoft Build:Tom and the panel unpack Copilot tuning, Model Context Protocol (MCP), and game-changing multi-agent orchestration that makes AI more adaptable and enterprise-ready than ever before.Smart Collaboration Updates in Teams:Threaded replies, streamlined file sharing with external users, and deeper AI integrations make team chat and channel work more intuitive and secure.Copilot in Teams – Deep Dive:Intelligent Recap now includes shared screen content, audio summaries, and real-time agents in meetings — taking productivity to new heights.Teams Phone & Teams Rooms Innovations:From transient transcription in sensitive calls to long-awaited call-waiting beeps and full speaker recognition for Android Rooms, the UC experience is expanding fast.Next Steps:Tune in to InfoComm (June 7–13) and CCW (June 9–12)Don't miss Commsverse (June 18–19)Apply for the UC Awards before June 20Watch the full episode to hear more about the community sessions and fireside chats coming this month.Thanks for watching, if you'd like more content like this, don't forget to SUBSCRIBE to our YouTube channel.You can also join in the conversation on our Twitter and LinkedIn pages.Join our new LinkedIn Community Group.

Send us a textWelcome back for the conclusion of my interview with Professor, bestselling Author, and Retired ATF Special Agent Jay Dobyns. If you're enjoying this episode, you'll love my interview with ATF Special Agent Ken Croke from episode 120, where he chats about his deep undercover mission taking down the outlaw motorcycle gang, The Pagans. I thought it would be interesting to get a different perspective on these clubs by interviewing the former president of the Ventura Hells Angels, George Christie. That interview will go live next Sunday!Jay Dobyns spent over two decades as a federal agent embedded in the dark heart of America's violent crime, participating in more than five hundred undercover missions targeting gun runners, narcotics traffickers, explosives manufacturers, murder-for-hire schemes, and vicious gangs.Jay's most infamous case—a landmark infiltration of the Hells Angels motorcycle gang—changed the face of undercover work forever, earning him international recognition.Jay's story is more than headlines and danger. It's about the cost of service to others, the toll on identity, family, and mental health, and how to rise from it stronger.  In today's episode we discuss:·      Attempting to be a good dad and father, while you were undercover. How did you and your family deal with all of that?  ·      Sunny Barger, who he was and Jay's relationship with him.·      What kind of bike the ATF gave Jay. Why only Harleys or maybe Indians?·      Mafia on two wheels?. ·      What is the filthy few?·      What happened at Laughlin?·      His informant, Pops, and Black Biscuit.·      Deep undercover, the effects on him and his family. ATF help? Debrief after the case?.·      How did you leave UC work??·      A surfing Hells Angel?·      How close he came to losing his own identity.·      His advice for someone who wants to do deep UC work.·      The book, No Angel: My Harrowing Undercover Journey to the Inner Circle of the Hells Angels. Why write it and how did the process of writing the book affect him?Learn more about Jay Dobyns and his books on his website!Check out the new Cops and Writers YouTube channel!Check out my newest book, The Good Collar (Michael Quinn Vigilante Justice Series Book 1)!!!!!Enjoy the Cops and Writers book series.Please visit the Cops and Writers website.What would you do if you lost the one you loved the most? How far would you go to quench your thirst for vengeance?https://a.co/d/2UsJPbaSupport the show

SUBSCRIBE to The One to Go Show presented by ImpactHealth SharingSoil & Ag Solutions- https://www.agconcepts.com/  320-219-3542Daytona1- https://www.daytona1.com/ Fast Lane Motorsports and powdercoating- http://www.fastlanemotorsports.orgEastCentral Sports- http://www.eastcentralsports.comFB- https://www.facebook.com/OnetoGoShowSpotify: https://open.spotify.com/episode/4fO19zPyhuwqb74Ut3jgho?si=clWSn-DVQkmp8W_f95p4IgTikTok- @theonetogoshowSnapchat-@theonetogoshowRumble:  https://rumble.com/v57phvx-71524-the-one-to-go-show-presented-by-impact-health-sharing.htmlYouTube: https://www.youtube.com/channel/UC_r_TSMx2XEfMfJ9Vc1ez0w?view_as=subscriberWe'd like to hear from you: theonetogoshow@gmail.comA productionof G.O.A.T. Sports Media LLC

Send us a textAmanda Phillips never imagined her lifelong battle with Crohn's disease would transform into a business helping other people living with chronic illnesses. But after decades of unexplained stomach pains, missed diagnoses, and learning to navigate life with IBD, that's exactly what happened.Amanda takes us through her journey from childhood stomach aches dismissed as "just constipation" to her eventual diagnosis at 17. We explore how she learned to identify her personal flare triggers—stress and GI bugs being the major culprits—and the profound anxiety this created around situations most people take for granted, like commuting to work or being around sick family members.The pandemic became an unexpected turning point in Amanda's health journey. Working remotely eliminated the bathroom-related stress of her daily commute. When her company pushed employees back to the office, Amanda fought for accommodations, facing frustrating resistance from HR despite documentation showing remote work improved her health and performance.The birth of Be Well came during a February 2022 hospitalization, when Amanda found herself freezing in a standard hospital gown. Looking around at the medical wear available, she thought, "I can do better than this." What makes Amanda's approach unique is her commitment to meaningful design. Every Be Well product—from symptom tracking journals to discreet pill holders to comfort items with inspirational quotes—comes from lived experience and continuous customer feedback with a focus on prioritizing patient comfort, dignity, and practicality. Now she's expanding into new territory with hospital gowns, non-metal MRI hoodies, and more innovations. Whether you're living with chronic illness or supporting someone who is, this episode offers inspiration in turning personal challenges into purpose and creating solutions that truly understand patient needs.Links: Link to the BeWell websiteLink to BroGloInformation about IBD and work- Crohn's & Colitis Foundation- USAMy guest co-host, Stacey Calabro's episodeLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Dr. Adam Summers is a Professor in the School of Aquatic and Fisheries Sciences and Department of Biology at the University of Washington, and he conducts research in his lab within the Friday Harbor Laboratories there. With a background in engineering and mathematics, Adam works on applying engineering and physics principles to living systems. He uses lessons from the natural world to develop solutions to real-world problems like how to filter things, stick to things, burrow in sand, and move quickly and efficiently under water. Adam and his family live on a small island where they enjoy hiking and hanging out by the sea shore together. In addition, Adam is a licensed pilot, so you can often spot him spending his free time flying small planes. He completed his bachelor's degree in mathematics and engineering at Swarthmore College, and afterwards worked as a SCUBA instructor in Australia. Adam next decided to pursue graduate school, receiving his master's degree in Biology from New York University and his PhD in Organismic and Evolutionary Biology from the University of Massachusetts. He received a Miller Research Postdoctoral fellowship to conduct research at the University of California, Berkeley and went on to serve as a faculty member at UC, Irvine before joining the faculty at the University of Washington. Adam has been named a Fellow of the American Association for the Advancement of Science. In addition, he was awarded the Bartholmew Prize for physiology research from the Society of Integrative and Comparative Biology, the UC, Irvine Academic Senate prize for undergraduate teaching, as well as the Directors award for program management excellence from the National Science Foundation. He also writes a monthly biomechanics column in Natural History Magazine and served as scientific advisor for the Pixar films “Finding Nemo” and the recently released sequel “Finding Dory”. Adam is here with us today to talk a little about his research and tell us all about his journey through life and science.

An adult man dealing with past trauma goes on a killing spree in New York City. Retro Reel is back for the 2nd run on the podcast and we are starting a whole month of 80's horror films with Maniac. This is the 2nd time we watched the movie and while the film is at times a mess, it conveys how a traumatic event in the past causes the main character to experience violent urges. The film is entertaining as it does have some gruesome kills including one that may be one of the best all time horror movie kills due to the effects, however it does feature a lot of nonsense. One thing is for sure, there's a lot of moaning, potential schizophrenia, and dolls. Watch the movie and catch our review.Subscribe to our YouTube channel @thefinalpodcast  Join the Discord | https://discord.gg/UFtVP243Follow us on Facebook The Final Podcast Follow us on Instagram @thefinalpodcastFollow us on X @thefinalpodeverMusic Credit: Karl Casey @ White Bat Audiohttps://www.youtube.com/channel/UC_6h...What should we review next? Toss us a vibe and send over a recommendation!

Welcome to the daily304 – your window into Wonderful, Almost Heaven, West Virginia.   Today is Monday, June 2, 2025  UC's Business Accelerator Program helps West Virginians looking to grow their business…job opportunities abound in construction trades throughout West Virginia…and take the next step toward advancing your career by signing up for a WorkForce WV Statewide Virtual Job Fair…on today's daily304.   #1 – From UCWV– Are you looking to start or grow a business? Sign up for the Business Accelerator Program at the University of Charleston's Downtown Innovation Hub. To be a sophisticated business owner, you need a systematic way to grow your business. The skilled professionals at UC DIH have worked with dozens of growth companies from startups to multi-million-dollar enterprises to develop a systems approach that brings clarity to business management, enabling you to scale up and grow your business. Learn more: https://www.ucwv.edu/innovation/dih/   #2 – From METRO NEWS – Those with the construction trades in West Virginia say technology has transformed and added opportunities for those looking for job opportunities in the Mountain State. Affiliated Construction Trades West Virginia Executive Director Justin Williams says a wide range of good-paying jobs are available for people willing to sweat and work with their hands. Several members of the trades from West Virginia are in Ohio working on the construction of a microchip plan. Closer to home, there is the major bridge project over the Monongahela River in Morgantown, work on the WVU campus, a new Mon Health facility in the Bridgeport area and the $20 million Morris Family Health and Fitness Complex at Glenville State University. “The studies say over the next 15 years a great number of trades members are going to be retirement-eligible,” Williams said. “I'm not saying they're going to retire, but we need to train the workers to be able to fill those positions.” Read more: https://wvmetronews.com/2025/05/27/officials-say-skilled-trades-jobs-available-in-west-virginia/   #3 – From WORKFORCE WV– Are you a West Virginia job seeker looking to change or advance your career? Through the Virtual Statewide Job Fairs, you can chat with multiple organizations that are hiring all across West Virginia!  As an attendee, you can apply, live chat, video chat and interview virtually with employers participating in the event.  Virtual job fairs are scheduled for June 4, July 2 and August 6. Register now and take the next step toward starting or advancing your new career! Read more: https://workforcewv.org/statewide-virtual-job-fairs/   Find these stories and more at wv.gov/daily304. The daily304 curated news and information is brought to you by the West Virginia Department of Commerce: Sharing the wealth, beauty and opportunity in West Virginia with the world. Follow the daily304 on Facebook, Twitter and Instagram @daily304. Or find us online at wv.gov and just click the daily304 logo.  That's all for now. Take care. Be safe. Get outside and enjoy all the opportunity West Virginia has to offer.

Pronunciation, Sumo Facts, Rice Hot Take, and more! 言語学習と発音、大相撲の豆知識、米のホットテイクなど！ Join our Discord: https://discord.gg/VGSd94Tp4P Join our Book Club! https://ko-fi.com/i/IF1F01EWI60 Support on ko-fi:  https://ko-fi.com/lazyfluency Main channel:  https://www.youtube.com/channel/UC-8_djC5_aV4Mi3o3fuLPLA Send us questions at:  lazyfluency@gmail.com  

Welcome to the daily304 – your window into Wonderful, Almost Heaven, West Virginia.   Today is Saturday, May 31, 2025  A UC graduate shares how the university's rigorous physician's assistant program prepared her for her new career…plan an adventure for you and your dog in West “Fur”ginia (it's a ruff life!)...and the Mountain State Innovators Summit offers the opportunity for youth and college students to pitch their great ideas…on today's daily304. #1 – From UNIVERSITY OF CHARLESTON – In this edition of Discover UC, President Marty Roth sits down with Katelyn Barnhart, a proud Logan, West Virginia native and member of the Physician Assistant Program Class of 2025.  Katelyn shares her journey through UC's rigorous PA program and how it has prepared her for the next step—beginning her career at CAMC Women's and Children's Hospital. Watch now: https://www.youtube.com/watch?v=c3VjIt42-OM   #2 – From WV LIVING – Like all good mountaineers, West Virginia's furry friends are built for adventure. From the pet-friendly atmosphere of Shepherdstown to the luxurious accommodations of The Blennerhassett to the winding trails of the New River Gorge, West Virginia is a veritable playground for you and your pet to explore. And explore you should! The folks at WV Living have prepared a guide featuring all the tips, tricks, and advice you need to make sure everyone has a ball. So grab your leashes, pack a doggy bag, and get started planning your next fur-tastic excursion. Read more: https://wvliving.com/west-furginia/   #3 – From WVU – The Mountain State Innovators Summit is a three-day, two-night experience designed to empower the next generation of young talent in West Virginia. Hosted by West Virginia University Extension and the WVU Morris L. Hayhurst LaunchLab, this summit brings together youth, college students and early-stage entrepreneurs for hands-on coaching, meaningful networking and real-world opportunities. The event features eight live pitch competitions with a total of $300,000 in prizes and awards. The pitches will take place on November 13, 2025, during the Summit at Stonewall Resort. Learn more: https://extension.wvu.edu/community-business-safety/community-and-economic-development/equity-in-youth-entrepreneurship/mountain-state-innovators-summit   Find these stories and more at wv.gov/daily304. The daily304 curated news and information is brought to you by the West Virginia Department of Commerce: Sharing the wealth, beauty and opportunity in West Virginia with the world. Follow the daily304 on Facebook, Twitter and Instagram @daily304. Or find us online at wv.gov and just click the daily304 logo.  That's all for now. Take care. Be safe. Get outside and enjoy all the opportunity West Virginia has to offer.

Scott Springer of Cincinnati.com joined us from Knoxville to preview the NCAA Baseball Tournament and the upcoming games for UC and Miami. Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

Chad Brendel fills in for Mo and reacts to UC's Upset win over Wake Forest in their first game of the NCAA Tournament and a Reds Win over the Chicago Cubs.

Scott Springer of Cincinnati.com joined us from Knoxville to preview the NCAA Baseball Tournament and the upcoming games for UC and Miami. Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

Chad Brendel fills in for Mo and reacts to UC's Upset win over Wake Forest in their first game of the NCAA Tournament and a Reds Win over the Chicago Cubs.

SUBSCRIBE to The One to Go Show presented by ImpactHealth SharingSoil & Ag Solutions- https://www.agconcepts.com/  320-219-3542Daytona1- https://www.daytona1.com/ Fast Lane Motorsports and powdercoating- http://www.fastlanemotorsports.orgEastCentral Sports- http://www.eastcentralsports.comFB- https://www.facebook.com/OnetoGoShowSpotify: https://open.spotify.com/episode/4fO19zPyhuwqb74Ut3jgho?si=clWSn-DVQkmp8W_f95p4IgTikTok- @theonetogoshowSnapchat-@theonetogoshowRumble:  https://rumble.com/v57phvx-71524-the-one-to-go-show-presented-by-impact-health-sharing.htmlYouTube: https://www.youtube.com/channel/UC_r_TSMx2XEfMfJ9Vc1ez0w?view_as=subscriberWe'd like to hear from you: theonetogoshow@gmail.comA productionof G.O.A.T. Sports Media LLC

Join Magdalena Grace with her New Moon Runes Reading & Ritual   FIND OUT MORE ABOUT MAGDALENA GRACE HERE or TO SIGN UP FOR HER UPCOMING ABUNDANCE ALCHEMIST IN PERSON WORKSHOPS OR HEALTHY N WEALTHY N WISE RETREATS BOOK A RUNES READING AND SIGN UP FOR HER WORKSHOPS & MORE! www.MagdalenaGrace.com   JOIN OUR HEALTHY N WEALTHY N WISE ONLINE ACADEMY WITH OR WITHOUT AYAHUASCA MICRODOSING HERE:    www.microdosingforhealth.com    BUY ME A COFFEE OR DONATE FOR SCHOLARSHIP FUND FOR HEALING CLIENTS IN NEED https://venmo.com/u/lotusthrone   MORE ALCHEMY OPPORTUNITIES FOR YOUR BEST HEALTH, WEALTH AND RELATIONSHIPS www.LotusThroneSanctuary.com   WANNA SIGN UP AND BE A PLEDGING PATRON FOR HEALTHY N WEALTHY N WISE - SAVING LIVES AND CREATING MORE ABUNDANCE FOR OTHERS?  https://patron.podbean.com/magdalena     SUBSCRIBE TO HER YOUTUBE CHANNEL: https://www.youtube.com/@UC_l0t_6TBbZ1q9Q0wKZz89Q